abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

14 Jul 2009

Author:
Graham Ruddick, Telegraph [UK]

GlaxoSmithKline to inject £60m into HIV and Aids drugs in Africa

GSK will create a new Positive Action for Children Fund that will have access to £50m over the next 10 years, and has also granted Aspen Pharmacare, in which it acquired a 16pc stake in May, a royalty-free licence to develop a cheaper, generic version of its HIV treatment abacavir... MP David Borrow, chairman of the All Party Parliamentary Group on Aids, said he welcomed GSK's new commitments, but added: "GSK is taking positive steps, but they are broadly unilateral, which will limit their impact. We would like to see them work with Unitaid to create a patent pool which gives fair royalties for their patents." [also refers to Pfizer]